References
- Sourbier C., Massfelder T. Parathyroid hormone‐related protein in human renal cell carcinoma. Cancer Lett 2006; 240((2))170–82
- Yoneda T., Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005; 328((3))679–87
- Raubenheimer E. J., Noffke C. E. Pathogenesis of bone metastasis: a review. J Oral Pathol Med 2006; 35((3))129–35
- Heider U., Fleissner C., Zavrski I., Kaiser M., Hecht M., Jakob C., Sezer O. Bone markers in multiple myeloma. Eur J Cancer 2006; 42((11))1544–53
- Corey E., Quinn J. E., Bladou F., Brown L. G., Roudier M. P., Brown J. M., Buhler K. R., Vessella R. L. Establishment and characterization of osseous prostate cancer models: intra‐tibial injection of human prostate cancer cells. Prostate 2002; 52((1))20–33
- Bonfil R. D., Dong Z., Trindade Filho J. C., Sabbota A., Osenkowski P., Nabha S., Yamamoto H., Chinni S. R., Zhao H., Mobashery S., Vessella R. L., Fridman R., Cher M. L. Prostate cancer‐associated membrane type 1‐matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth. Am J Pathol 2007; 170((6))2100–11
- Rosen L. S., Gordon D., Tchekmedyian N. S., Yanagihara R., Hirsh V., Krzakowski M., Pawlicki M., De Souza P., Zheng M., Urbanowitz G., Reitsma D., Seaman J. Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double‐blind, placebo‐controlled trial. Cancer 2004; 100((12))2613–21
- Boyce B. F., Yoneda T., Guise T. A. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999; 6((3))333–47
- Yano S., Macleod R. J., Chattopadhyay N., Tfelt‐Hansen J., Kifor O., Butters R. R., Brown E. M. Calcium‐sensing receptor activation stimulates parathyroid hormone‐related protein secretion in prostate cancer cells: role of epidermal growth factor receptor transactivation. Bone 2004; 35((3))664–72
- Smith P. C., Hobisch A., Lin D. L., Culig Z., Keller E. T. Interleukin‐6 and prostate cancer progression. Cytokine Growth Factor Rev 2001; 12((1))33–40
- Brown J. M., Corey E., Lee Z. D., True L. D., Yun T. J., Tondravi M., Vessella R. L. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001; 57((4))611–6
- Lee Y., Schwarz E., Davies M., Jo M., Gates J., Wu J., Zhang X., Lieberman J. R. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 2003; 21((1))62–72
- Zhang J., Dai J., Qi Y., Lin D. L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J., Keller E. T. Osteoprotegerin inhibits prostate cancer‐induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107((10))1235–44
- Chomczynski P., Sacchi N. Single‐step method of RNA isolation by acid guanidinium thiocyanate‐phenol‐chloroform extraction. Anal Biochem 1987; 162((1))156–9
- Horwood N. J., Kartsogiannis V., Quinn J. M., Romas E., Martin T. J., Gillespie M. T. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999; 265((1))144–50
- Inoue H., Nishimura K., Oka D., Nakai Y., Shiba M., Tokizane T., Arai Y., Nakayama M., Shimizu K., Takaha N., Nonomura N., Okuyama A. Prostate cancer mediates osteoclastogenesis through two different pathways. Cancer Lett 2005; 223((1))121–8
- Yamamoto Y., Udagawa N., Matsuura S., Nakamichi Y., Horiuchi H., Hosoya A., Nakamura M., Ozawa H., Takaoka K., Penninger J. M., Noguchi T., Takahashi N. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor‐kappaB ligand. Endocrinology 2006; 147((7))3366–74
- Keller E. T., Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004; 91((4))718–29
- Blair J. M., Zheng Y., Dunstan C. R. RANK ligand. Int J Biochem Cell Biol 2007; 39((6))1077–81